US equities |
SPCX $175.20 ▲+2.40% NVDA $242.09 ▲+1.34% MU $1,064.99 ▲+0.10% MRVL $289.50 ▲+6.73% AMD $645.57 ▲+2.19% SNDK $1,674.51 ▼-1.74% TSLA $381.17 ▲+0.65% AVGO $376.67 ▲+3.90%
FinancialContent

Akebia Therapeutics, Inc. - Common Stock (NQ:AKBA)

0.8801 -0.0304 (-3.34%)
Delayed Quote Updated: 10:19 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akebia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Akebia Therapeutics (NASDAQ:AKBA) Slides 24.6% Despite Q2 Earnings Beat ↗
Via Chartmill
News headline image
Akebia Therapeutics Q2 Earnings Call Highlights ↗
Akebia Therapeutics (NASDAQ:AKBA) reported second-quarter revenue growth for its Vafseo anemia treatment while highlighting an interim clinical result from the VOICE study and progress across its... 
Via MarketBeat
Topics Earnings
News headline image
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near ↗
Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a... 
Via MarketBeat
Topics Intellectual Property
News headline image
Akebia (AKBA) Q1 2026 Earnings Transcript ↗
Akebia (AKBA) Q1 2026 Earnings Transcript 
Via The Motley Fool
Akebia Therapeutics Inc (NASDAQ:AKBA) Reports Q4 Revenue Beat and 49% Annual Growth Amid Mixed Market Reaction ↗
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
An Overview of Akebia Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Akebia (AKBA) Q4 2025 Earnings Call Transcript ↗
Akebia (AKBA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction ↗
The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027. 
Via Stocktwits
News headline image
Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M ↗
The company said that the sale extends its cash runway into the second half of 2027. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview For Akebia Therapeutics ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November ↗
 
Via Benzinga
News headline image
FDA Pushback Prompts Akebia To Drop Broad Label Pursuit For Kidney Disease Drug ↗
Akebia shares decline after the company ends plans for its VALOR trial, citing FDA feedback and high costs tied to expanding Vafseo's label. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Insights Ahead: Akebia Therapeutics's Quarterly Earnings ↗
 
Via Benzinga
News headline image
Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Akebia (AKBA) Q2 Revenue Jumps 43% ↗
Via The Motley Fool
News headline image
9 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Top movers in Thursday's session ↗
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >